Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine |
| |
| Authors: | Olga Grinberg Aharon Gedanken Debabrata Mukhopadhyay Chitta Ranjan Patra |
| |
| Institution: | 1. Department of Chemistry, Kanbar Laboratory for Nanomaterials, Nanotechnology Research Center, Institute of Nanotechnology and Advanced Materials, Bar‐Ilan University, , Ramat‐Gan, 52900 Israel;2. Department of Biochemistry and Molecular Biology & Biomedical Engineering, Mayo Clinic, , Rochester, Minnesota, USA;3. Centre for Chemical Biology, Indian Institute of Chemical Technology (CSIR‐IICT), , Hyderabad, 500607 AP, India |
| |
| Abstract: | Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over‐expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti‐EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico‐chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti‐EGFR (BSA‐Gem‐EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA‐Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface. Copyright © 2012 John Wiley & Sons, Ltd. |
| |
| Keywords: | BSA microspheres Sonochemistry anti‐EGFR monoclonal antibody gemcitabine pancreatic cancer cells (AsPC1) targeted drug delivery |
|
|
